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INTEGRATED CORRELATION ANALYSIS OF PROTEOMICS AND 
TRANSCRIPTOMICS DATA IN ALZHEIMER’S DISEASE 
 
Abstract 
Neurodegeneration is the umbrella term for a range of conditions which include various types of 
conditions like Progressive Supranuclear Palsy (PSP), Alzheimer’s disease (AD), and Huntington’s 
disease which involve the death of neurons. Once the neurons die, they cannot be replaced. The 
Alzheimer's Association has mentioned in their facts and figures that Alzheimer’s disease (AD) is 
thought to begin at least 20 years before the symptoms are seen. The Association further categorized 
AD into five broad stages based on the CERAD score [1]. AD destroys cognitive functioning and 
thinking as it progresses. However, disease-modifying treatment is yet not there [2,3,4]. For some years 
now, researchers have successfully worked on the disease with individual omics layers. With the rise 
in next-generation sequencing technologies and the reduced cost of sequencing, it is now possible to 
integrate large datasets that facilitate information pertaining to biology. Thus, it is now a known fact 
that there is an excellent interplay between the omics layers contrary to what is laid down by the central 
dogma [5]. However, co-immunoprecipitation methods can confirm the actual cross talks. There are 
also numerous integrated studies like network analysis, principal component analysis, clustering, 
correlation analysis, and predictive analysis to understand the associations between the different omics 
layers. We wanted to see if there existed any significant correlations between two -omics layers. So, 




performing the differential expression of two datasets (proteomics and transcriptomics) individually. 
An in-depth analysis of the proteomics data was performed, followed by differential expression analysis 
of RNA seq data and then a correlational analysis of the differentially expressed proteins (from 
proteomics data) and genes (from RNA seq data). From our analysis, we found fascinating information 
about the correlations between proteins and genes in AD. We performed a correlation analysis of AD 
(N= 84), Control (N = 31), and PSP (N = 85) samples for proteomics data and got 114 differentially 
expressed proteins (DEPs = 114). The RNA seq data had AD (N = 82), Control (N = 31) and PSP (N 
= 84) samples which gave us 61 differentially expressed genes (DEGs = 61).  A correlation analysis 
using Spearman’s correlation coefficient method between proteins involved in AD revealed 192 very 
significant correlations with p-value <= 0.00000000000005. The mean correlation coefficient was quite 
high (r = 0.52). A correlation analysis using Spearman’s correlation coefficient method between genes 
involved in AD revealed 208 very significant correlations with p-value <= 0.00000000000005. The 
mean correlation coefficient was quite high (r = 0.52). A correlation analysis using Spearman’s 
correlation coefficient method between proteins and genes involved in AD revealed 395 significant 
correlations with p-value <= 0.0001. The correlation coefficient (quite high of +0.53), which might 
help in understanding the molecular pathways behind the disease could uncover new prospects of 
understanding the disease as well as design treatments. We observed that different genes interact with 
different proteins (correlation coefficient r >= 0.5, p-value < 0.05). We also observed that a single 
protein interacts with multiple genes, and a single gene is interestingly associated with multiple 
proteins. The patterns of correlations are also different in that a protein/gene positively correlates with 
some proteins/genes and negatively with some other proteins/genes. We hope that this observation is 
quite useful. However, understanding how it works and how they interact with each other needs further 
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Chapter 1: Introduction 
 
Fig1: AD facts and figures as given by Alzheimer’s Association 
The data from statistical facts and figures for 2020 by Alzheimer's Association shows that at least 5.8 
million Americans have Alzheimer's Disease (AD), of which 1 million (17%) are in the age range of 
65-74 years, 2.7 million (47%) are in between 75-84 years and 2.1 million (36%) are above 85 years of 
age. This number is thought to reach 13.8 million by 2050. Alzheimer's Association has mentioned in 
its facts that AD is thought to begin at least 20 years before the symptoms are seen. The Association 
further categorized AD into five broad stages based on the CERAD score [1]. Stage-1 is the Preclinical 
AD with no symptoms, stage-2 is a mild cognitive impairment (MCI) that do not interfere with daily 
activities, stage-3 is mild but interferes with daily activities, stage-4 is moderate AD interfering with 
most daily activities, and the final stage is stage-5 in which the symptoms interfere with all daily 




symptomatic treatments available for AD, namely donepezil, rivastigmine, galantamine, and 
memantine, but they do not play a role in actually decelerating or preventing the progression of the 
disease [3]. While protein aggregation is the hallmark of any form of neurodegeneration (Lee et al., 
2011), the disease's molecular epidemiology is still under debate. Researchers believe that the disease 
begins when amyloid-beta begins to accumulate. Beta-amyloid 42, formed from the proteolytic 
breakdown of amyloid precursor protein (APP), is a very toxic form of beta-amyloid, as stated by the 
National Institute of Aging. Abnormal quantities of this naturally occurring protein form plaques 
between the synapses, causing a neurodegenerative condition leading to AD. Abnormal accumulation 
of neurofibrillary tangles called Tau accumulation inside the neurons due to the hyperphosphorylation 
of microtubule-associated protein (MAPT) is also a cause of AD. The beta-amyloid is normally cleared 
off by the microglia, but sometimes, too much is released, and among the synapses and not enough of 
it is cleared away [4,5]. Like AD, PSP also involves the abnormal deposition of hyperphosphorylated 
tau. The difference is that abnormal deposition of amyloid-beta plaques is absent in PSP. PSP and AD 
also differ in the type of tau protein deposition. The AD-type hyperphosphorylated Tau is different 
from PSP-type hyperphosphorylated Tau in its isomers formed due to alternative splicing [6]. There 
are numerous integrated studies done to understand the interactions occurring between the different 
omics layers. For example, (Singhal et al., 2019) proposed a pathway-centric neural-network-based 
omics integration analysis [6]. (Dragomir et al., 2019) reviewed the current state-of-the-art integrated 
framework focusing on finding network-based biomarkers at molecular and brain functional 
connectivity levels [7]. (Avramouli & Vlamos, 2016) highlighted the most recent next-generation 
sequencing technologies that have enabled a sophisticated analysis of the human genome [8].  A 
correlation analysis is a very good way to look at how two quantitative variables form pairs with each 




and PSP.  Mathematically, correlation is defined as the degree of relationship or association between 
two variables. When two variables or two datasets show a high correlation, we can infer that they are 
closely linked. So, when we do a correlation, we can either look at how one variable tends to change 
with respect to the other, or how both the variables change together. Sometimes If one variable is large, 
another variable may become smaller or larger. Also, the relationship between two variables can be 
positive if high measures of one variable correspond to high measures of another variable or the 
relationship between two variables can be negative if high measures of one variable correspond to low 
measures of another variable (Gonick et al., 2003). In any case a correlation may not be causation. So, 
there can exist a high correlation between two variables with no causations at all. They are just the 
predictors of each other. The + or - of the correlation coefficient (which depicts both a direction and 
magnitude) tells that there exists a relationship between the two, with + being a positive relationship, - 
being a negative relationship, and the number indicating the magnitude or the value of the relationship. 
Many studies show that there is a very poor correlation between mRNA and proteins. The discrepancy 
is typically attributed to regulation levels between transcript and protein products (Maier et al., 2009). 
Advances in next-generation sequencing technologies and methods and mass spectrometry proteomics 
provide an unparalleled ability to survey mRNA and protein abundances helping researchers to explore 
the extent to which different aspects of gene expression help to regulate cellular protein abundances 
(Vogel et al., 2012). Data demonstrates that the regulatory processes that occur after mRNA are made 
are myriad, like post-transcriptional regulation, post-translational regulation, and protein degradation 
regulation (Fekete et al., 2012), controlling steady-state protein abundances. Most mRNA-protein 
correspondence studies calculate a single correlation coefficient representing a correlation between 
mRNA expression and protein expression across all genes. The correlation between mRNA and protein 




across the entire genome. The correlation coefficient represents the correlation between the expression 
of an mRNA and its protein product across multiple samples or conditions (Koussounadis et al., 2015). 
So, since our focus was to find correlations between proteins (proteomics) and genes (transcriptomics) 







Chapter 2: Materials and Methods 
 
2.1: Experimental design and data download: 
The data sets were downloaded from open-source platform synapse.org-MayoRNAseq study (Synapse 
ID: syn5550404). This study is independent of studies described under the Mayo Clinic Alzheimer's 
Disease Genetics Studies (MCADGS). The data in the MayoRNAseq study consists of whole 
transcriptome data for 276 Temporal cortex (TCX) samples from 312 North American Caucasian 
subjects. The brain samples are a single cohort diagnosed with neuropathological conditions of 
Alzheimer’s Disease (AD) and Progressive Supranuclear Palsy (PSP). Controls (C) were those elderly 
patients that did not have any neurodegenerative condition. Within this cohort, all AD, PSP and Control 
subjects were from the Mayo Clinic Brain Bank (MCBB). All subjects selected from the MCBB 
underwent neuropathologic evaluation [10]. All ADs had definite diagnosis according to NINCDS-
ADRDA criteria and had a Braak NFT stage of IV or greater [11]. Control subjects had Braak NFT 
stage of III or less, CERAD neuritic and cortical plaque densities of 0 (none) or 1 (sparse) and lacked 
any of the neurodegenerative pathologic diagnoses including AD, Parkinson's disease (PD), PSP, motor 
neuron disease (MND), Pick's disease (PiD), Huntington's disease (HD), hippocampal sclerosis 
(HipScl), dementia lacking distinctive histology (DLDH) or any other forms of dementias [10].  Under 
mentioned (Table 1) is the sample sizes for proteomics and transcriptomics data and their description 






Table 1: Summary of the datasets used in the analysis: 
 
 
2.1.1: Proteomics dataset description: 
The brain samples of elderly adults whose age was in the range of 65-90, Alzheimer's disease (AD; 
N=84), progressive supranuclear palsy (PSP; N=85), pathologic aging control (CON; N=31), were 
quantified using label-free (LFQ) based protocols followed by LC MS/MS analysis [10]. The output 
proteomics abundance dataset, "Mayo_proteomics_TC_proteinoutput.txt" and associated traits, 
"Mayo_proteomics_TC_traits.csv" were used for further bioinformatics and statistical analysis. RAW 
data for the samples was analyzed using MaxQuant v1.5.3.30 with Thermo Foundation 2.0 for RAW 
file reading capability. The search engine Andromeda, integrated into MaxQuant 1, was used to build 
and search a concatenated target-decoy Uniprot human reference protein database (retrieved April 20, 




adventitious proteins (cRAP) built into MaxQuant. Methionine oxidation (+15.9949 Da), asparagine 
and glutamine deamidation (+0.9840 Da), and protein N-terminal acetylation (+42.0106 Da) were 
variable modifications (up to 5 allowed per peptide); cysteine was assigned a fixed carbamidomethyl 
modification (+57.0215 Da). Only fully tryptic peptides were considered with up to 2 mis-cleavages in 
the database search. A precursor mass tolerance of ±20 ppm was applied prior to mass accuracy 
calibration and ±4.5 ppm after internal MaxQuant calibration. Other search settings included a 
maximum peptide mass of 6,000 Da, a minimum peptide length of 6 residues, 0.05 Da tolerance for 
high resolution MS/MS scans. Co-fragmented peptide search was enabled to deconvolute multiplex 
spectra. The false discovery rate (FDR) for peptide spectral matches, proteins, and site decoy fraction 
were all set to 1 percent. Quantification settings were as follows: re-quantify with a second peak finding 
attempt after protein identification has completed; match MS1 peaks between runs; a 0.7 min retention 
time match window was used after an alignment function was found with a 20-minute RT search space. 
Quantitation of proteins was performed using summed peptide intensities given by MaxQuant. The 
quantitation method only considered razor plus unique peptides for protein level quantitation. The full 
list of parameters used for MaxQuant are available as Mayo_Proteomics_TC_searchparameters.xml 
accompanying the public release [10]. The data has Synapse ID: syn7431760. 
2.1.2: Transcriptomics dataset description: 
Transcript read count data was available to be downloaded (Synapse ID: syn20818651). Gene 
expression measures were generated using next-generation RNA sequencing (RNAseq), at the MCBB 
Sun Health research institute from temporal cortex(TCX) for 278 subjects. Out of these 278 subjects, 




supranuclear palsy (PSP), 28 were diagnosed with pathologic aging (PA), and 80 were control (C) 
samples.  
Bioinformatics methods summary: SNAPR aligner was used for read alignment. The human reference 
genome version used for indexing were GRCh38 reference and Ensembl v77 gene models. The output 
files were gene counts and transcript counts for each sample.  We considered the transcript counts. QC 
was done to identify any subjects with mapped reads less than 85% or any sex-dependent (Y 
chromosome gene expression) using PLINK [13]. To identify any population outliers (defined as > 6 
standard deviations from the mean after 5 iterations), EIGENSTRAT was used [14]. All reads have 
PHRED score >= 20 [13,14,15,16]. 
To identify the genes that are differentially expressed across different conditions, a differential 
expression analysis using R package edgeR(empirical analysis of DGE in R) was performed. EdgeR 
also works like limma but mathematically is more complex (Robinson et al., 2010). Those differentially 
expressed genes were used for correlation analysis. PA (N = 84) samples were removed from the dataset 
to match the proteomics data set which had AD, PSP and C samples and lacked PA samples. For 
controls, 31 samples that matched the proteomics dataset were considered for differential expression 
analysis. Thus, we now had Alzheimer's disease (AD; N=82), progressive supranuclear palsy (PSP; 
N=84), and control (C; N=31) samples in our transcriptomics data set.  
2.1.3: Workflow employed in the analysis of the project: 
Following the fetching of data for proteomics and transcriptomics from synapse.org, we designed the 
workflow depicted below. In the first step, we cleaned and manipulated proteomics data (removed 




statistical analysis and protein co-expression analysis. RNA seq data was also processed in parallel and 
differential expression analysis was done. A correlation analysis of the differentially expressed proteins 
and genes was then carried out. 
 










2.2: Proteomics data analysis: 
2.2.1: Background: 
In a review paper (Lee et al., 2018) mentioned that neurodegenerative diseases like AD are not only 
painful to the person suffering from it but also a burden to the patient’s social relationships. They further 
assert that mass spectrometry is a robust technology to study protein abundances involved in a disease 
condition in which proteins are digested by trypsin and then analyzed by LC-MS/MS. A lot of research 
from the past (www.mayoclinic.org) suggests that a person who is the carrier e4 variant of the APOE 
gene (APOE e4) is at the highest risk of AD. Microtubule-associated protein tau (MAPT) is the major 
protein of a mature neuron, others being MAPT1 and MAPT2, which appear to be critical to regular 
brain activity in evolved species like humans.  MAPT has associated protein variants like MAP1A, 
MAP1B and MAP2. So, if microtubule associated protein tau 
(https://www.genenames.org/tools/search/#!/all?query=MAPT)   is non-functional, its functionality 
can be compensated by the other associated proteins. However, it is the toxicity of tau protein that 
affects a neuron's functionality, leading to a gradual eroding of the brain's structure leading to eventual 
functional loss. The hyperphosphorylation of tau protein is a result of an imbalance of activities 
between kinases and phosphates [16]. It is now clear that protein aggregation is the hallmark of 
neurodegeneration [17]. Here, to identify and to understand the molecular associations involved in AD, 
we performed an in-depth proteomic analysis of postmortem human elderly brains and later a 
correlation analysis of the proteins to understand the pairing of a protein with its neighboring proteins 
in AD with respect to PSP, controls and also with respect to each other (AD). We performed a pairwise 






Table 2: Summary of samples used in proteomics analysis:  
 
 
2.2.2: Data cleaning and preprocessing - Batch effects correction: 
 
Batch effects in proteomics often result in both, decreased intensities and increased number of missing 
values [17]. The protein abundance data which is an output data of MaxQuant is a single cohort with 5 
batches (namely b1, b2, b3, b4, b5) and 3 conditions (AD, Control, PSP). The dataset has 6585 rows 
representing human proteins and 2105 columns representing Label-free quantified (LFQ) intensities 
and other related information which included contaminants, m/z values etc. After filtering 
contaminants, there are 6335 human proteins in the rows and 2105 columns which included LFQ 
intensities along with other important information pertaining to the proteins. Within each batch, the 
data had pooled samples named after “mgis” that were the Mayo Global Internal Standards and “egis” 
that were the Emory Global Internal Standards as can be seen in table 1. Pooled samples are often added 
to proteomics experiments in order to overcome resource constraints when many individuals are 





For example, if  is biological variance and  is technical variance, then the expected variance in 
expression of protein in a sample of individuals,  is,  
                                                                        (1) 
The variance in a sample of pools each formed by combining equal amounts of total protein from r 
individual samples is,  
                                                                    (2) 
Thus Eq. (2) shows that the measured biological variance in a pool will decrease by a fraction 1/r. This 
reduction should increase the power to detect treatment differences. 
Pooled samples are normally prepared by taking a little (equal) amount of each sample, which is put 
into two aliquots and digested along with other samples, to serve as pooled Global Internal Standards 
(GIS) [20]. Though pooled samples reduce the biological variance, they are a major source of artifacts 


























2.2.3: Controlling for batch-specific variance:  
There were severe batch effects across the five batches in our proteomics dataset and the data needed 
to be cleaned. The data was pre-processed and cleaned by using TAMPOR MASTER which normalized 
the data and fixed the batch effects.  (Tunable Approach for Median Polish of Ratio -- Biological 
Abundance Batch Effect Removal).  (https://github.com/edammer/TAMPOR) [22]. TAMPOR 
(available as an R script) implements a median polish algorithm to adjust technical variance due to 
multiple samples, cohorts, or batches. The algorithm implements several iterations of equation (1) 
below. 
   x                                  (1) 
The algorithm implements equation (1) for each protein abundance measurement across each sample 
for all samples converting them into median-centered abundance measurements. The matrix is then 
log2 transformed. Each log2 ratio is then adjusted by subtracting the sample log2 ratio median for each 
protein. The ratios are then anti-logged. Row wise median of all samples is then multiplied to the anti-
logged ratios. This process is iterated until convergence. The algorithm reduces technical variance and 
preserves the biological variance [23]. It works well even if batch replicates for normalization have 
unusual variance compared to biological samples not used for normalization (e.g., due to differential 
peptide digestion, different tissue region, or different genetic background of control samples) [23]. The 
output obtained was a normalized dataset which was used to carry out the rest of the analysis. As 
mentioned in Table 1, there were two GIS samples (“mgis” and “egis”).  We considered “mgis” samples 
for removal of batch effects. TAMPOR also gave the plots before and after batch effect removal. In 




is very discrete and heterogenous. But on the right is the plot after batch effects were removed.  Now 
the data was ready for further analysis.  
 
 
Figure 3: MDS plot of the data before and after batch effect removal. Colour scheme: Green = Control (31), Red = 
AD (84), Blue = PSP (85).  
Since the proteomics dataset is prepared using label free quantification methods, we needed only LFQ 
intensity values for all five batches from the data set. These LFQ intensity values were selected and 
extracted for AD, PSP and C samples. So, now our data had 6335 rows representing proteins and 215 
columns with LFQ intensities (of samples). The Traits file has lines 1:200 – samples (LFQ intensities), 
lines 201:215 – egis samples (removed), lines 216:230 – ‘mgis’ samples. 
2.2.4: Missing values and imputation:  
The abundance of missing values due to technical or biological reasons is a prominent characteristic of 
proteomics data that can bias every normalization procedure and violate the distributional assumptions 
that are foundations of normalization [24,25]. So, before any normalization is carried out, missing 
values must be tackled. The missing values in the dataset were removed while correcting batch effects 




values and was imputed by replacing the missing values with the median observation for each protein 
under each condition. 
 
2.2.5: Quantile normalization:  
The aim here is to give different distributions the same statistical properties by removing the technical 
variations between experiments. Mass spectroscopy-based quantification often compromises on the 
normalization steps before the downstream analysis is done. Normalizing proteomics data is necessary 
to remove the biases that arise due to non-biological variance/technical artifacts. [24,25]. Quantile 
normalization (QN) method was used to remove such unintended variation while retaining the 
biological signal of interest. QN considers the mean of the most expressed values across all samples 
and makes an empirical distribution of abundance values for each sample to be the same. So, the 
normalized dataset retains the rank of the protein/gene expression values as well as removes variance 
among the expression values. QN was applied to a matrix of proteins as rows and samples with LFQ-
intensity values as columns. The steps included sorting the proteins for each sample, finding the rank 
of values in each column, finding row mean on sorted columns, substituting mean values according to 
rank, and replacing each column's value with mean according to rank. Here, by rank, we mean sorting 





Figure 4: Plots before and after quantile normalization of the data 
 
2.2.6: Differential expression analysis: 
To analyze mass-spectrometry based proteomics data in which an effort is being made to compare 
disease to normal samples, a standard statistical method must be employed to obtain significant 
differentially expressed proteins (DEPs) across different experiments 
(https://www.sciencedirect.com/science/article/pii/S2212968515000069#bib0065).  
We used the Bioconductor package 'limma' to perform proteomics data analysis. Limma uses the 
Empirical Bayes method to analyze data (Smyth, G. K. (2004). Limma makes a pooled estimate to 
retain biological variance in the data by reducing the sample variances. A pooled estimate is an estimate 
obtained when combined information from two or more randomly selected samples having the same 
mean is taken. Thus, the analysis becomes fully unbiased and more powerful than normal t-tests. 




First, the pooled variance is computed by computing within each protein's region variance and averaged 
across all proteins. The pooled variance is computed by creating a design matrix (A design matrix is a 
matrix whose columns give the coefficients of the linear model. There is one row for each sample) from 
traits data, computing the within-sample correlation for each protein and fitting the model to obtain the 
pooled variance. Next, a t-test is computed for each protein to get a list of significant DEPs based on 
p-values, adjusted p-values, or FDR estimates. We already had the dataset that was corrected for batch 
effects. Before performing the DEP analysis, we further imputed and normalized (QN) the dataset 
which was the input for further DEP analysis. As was essential, a design matrix was created, and linear 
model fitting was done. We performed a pairwise comparison of the experimental conditions with AD 
vs. Control, PSP vs. Control and AD vs. PSP. So, we had to build a contrast of each pairwise sample. 
Contrasts.fit() function was used to compute estimated coefficients and standard errors for a given set of 
contrasts (here, AD vs Control). The input for the contrasts.fit() was lmFit.  
 
2.2.6.1: Statistics for Differential Expression: 
 
Limma employs eBayes() function which returns a number of summary statistics for each protein. The 
logFC (log2-fold change) is the log2-expression level for that protein. AveExpr, the average expression 
level for that protein across all the samples. t is t-statistic which is the ratio of the logFC to its standard 
error. (t-statistic is the same as an ordinary t-statistic but the standard errors are moderated across 
proteins, so that information about each protein is an ensemble of information from all proteins. The p-
value is then obtained from t-statistic. Since the number of samples is many, multiple hypothesis 
correction is necessary to reduce the false positives. The FDR adjustment method used here was 'BH' 
(Benjamini and Hochberg's method). The B-statistic talks about the log-odds that a particular protein 




considering p-value (adj-p-value) to select differentially expressed proteins is a general 
practice. Limma’s eBayes() thus returned 405 proteins significantly downregulated and 321 
upregulated in AD vs. C samples. 346 proteins were significantly downregulated and 521 upregulated 
in PSP vs. C samples and 1240 proteins are significantly downregulated and 823 upregulated in AD vs. 
PSP samples as depicted in table 3.1, table 3.2 and table 3.3 respectively. 
 





          
logFC 
                   
     
AveExpr             t     P.Value 
    
Adj.P.Val           B 
H0YG30 0.685 27.101 8.127 0.00E+00 0.00E+00 21.349 
A6NMN0 0.833 29.329 7.28 0.00E+00 0.00E+00 16.488 
VAMP3 0.463 25.338 6.919 0.00E+00 0.00E+00 14.501 
TAU.1 0.844 30.912 6.673 0.00E+00 0.00E+00 13.188 
PLEC 0.537 25.819 6.567 0.00E+00 0.00E+00 12.63 
H0YFX9 0.462 30.405 6.542 0.00E+00 0.00E+00 12.498 
H7C545 0.829 29.007 6.306 0.00E+00 0.00E+00 11.278 
H0Y7G9 0.809 26.566 6.075 0.00E+00 0.00E+00 10.117 
X6RHB9 0.403 27.84 6.056 0.00E+00 0.00E+00 10.023 
E9PQN5 -0.384 25.91 -5.923 0.00E+00 0.00E+00 9.366 
AB17A 0.631 23.663 5.806 0.00E+00 0.00E+00 8.8 
H0YJI1 -0.322 27.909 -5.805 0.00E+00 0.00E+00 8.794 
A0A087X134 0.356 32.848 5.788 0.00E+00 0.00E+00 8.709 
E5RG36CON__P17697 0.367 31.652 5.746 0.00E+00 0.00E+00 8.511 













Table 4.2: Significant DEPs in the comparison of proteins in PSP vs Control samples 
 
PID 
               
logFC 
                
AveExpr 
          
t 
            
P.Value 
               
adj.P.Val 
        
B 
H0YHD8 0.373 31.417 6.349 0.00E+00 0.00E+00 
11.47
3 
E9PR42 -0.461 27.668 
-
6.107 0.00E+00 0.00E+00 
10.25
8 
E9PLK6 -0.459 30.495 -6.06 0.00E+00 0.00E+00 
10.02
2 
ANO1 0.509 28.938 5.873 0.00E+00 0.00E+00 9.112 
X6RHB9 0.383 27.84 5.767 0.00E+00 0.00E+00 8.601 
J3QRJ3 0.305 33.287 5.745 0.00E+00 0.00E+00 8.498 
ARHG6 -0.302 25.122 
-
5.735 0.00E+00 0.00E+00 8.45 
ARAID -0.556 37.127 
-
5.644 0.00E+00 0.00E+00 8.021 
C9JSB2 0.348 25.827 5.532 0.00E+00 0.00E+00 7.5 
M0QZC9 -0.386 25.117 
-
5.392 0.00E+00 0.00E+00 6.859 
MARF1 0.326 25.32 5.121 0.00E+00 0.00E+00 5.653 
G3XAK4 -0.308 28.575 
-
5.019 0.00E+00 0.00E+00 5.209 
A0A087WX
08 -0.357 26.053 
-
4.964 0.00E+00 0.00E+00 4.973 
H7C1N8 0.335 29.118 4.983 0.00E+00 0.00E+00 5.054 






























H7C545 1.422 29.007 14.777 0.00E+00 0.00E+00 66.177 
PLEC 0.842 25.819 14.077 0.00E+00 0.00E+00 61.305 
ARAID 0.944 37.127 13.075 0.00E+00 0.00E+00 54.322 
K7EKD1 1.381 28.46 12.204 0.00E+00 0.00E+00 48.285 
H0YD17 2.125 27.558 11.41 0.00E+00 0.00E+00 42.826 
ADDG 0.343 31.651 11.41 0.00E+00 0.00E+00 42.829 
PADI2 0.696 31.338 11.374 0.00E+00 0.00E+00 42.581 
H0Y933 0.479 24.95 11.312 0.00E+00 0.00E+00 42.16 
PLEC.1 0.475 35.299 10.999 0.00E+00 0.00E+00 40.029 
F2Z2Z8 0.545 29.647 10.911 0.00E+00 0.00E+00 39.433 
H0YG30 0.672 27.101 10.882 0.00E+00 0.00E+00 39.241 
A0A087X13
4 0.488 32.848 10.838 0.00E+00 0.00E+00 38.942 
AHNK 0.67 31.669 10.823 0.00E+00 0.00E+00 38.841 
PLCD1 0.531 29.489 10.629 0.00E+00 0.00E+00 37.532 












2.2.6.2: Inferential statistics and visualization: 
Taking the differentially expressed proteins, the following analysis and visualization was done for each 
pairwise comparisons (AD vs C, PSP vs C, AD vs PSP). 
2.2.6.3: Hierarchical clustering and heatmaps:  
 
Hierarchical clustering was performed to check which set of proteins show similar patterns and cluster 
together among the experimental conditions, using hclust R package followed by the generation of 
heatmaps. The input was normalized data with proteins in the rows and experimental conditions in the 
columns.  Pheatmap package in R was used to generate the heatmaps. Firstly, Euclidean distance 
between experiments for AD-Control samples was calculated and then for proteins corresponding to 
those samples (Figure 5.1, Figure 5.2). The data was filtered for AD vs Control samples according to 
a relaxed threshold of significance (p <0.05). Here, log fold change was set to 0.585 (log2(1.5)) which 
represents a 1.5x change. The colour and intensity of the boxes in the heatmap (Figure 5.3) are based 
on the expression changes of protein expressions. Red color represents up-regulated genes and blue 
represents down-regulated genes. White represents unchanged expression. The same was done for PSP 






Figure 5.1: Clustering of samples in the experimental conditions for the pairwise comparison in AD vs C and 







Figure 5.2: Hierarchical Clustering and heatmap (AD vs Control): Left:  Clustering with respect to samples (above), 
clustering with respect to proteins (below). Right: The rows represent proteins, and the columns represent AD and Control 
samples. All upregulated proteins are red in color and downregulated proteins are blue in color. The ones in white are those 








Figure 6.1: Clustering of samples in the experimental conditions for the pairwise comparison in PSP vs C and 










Figure 6.2: Hierarchical Clustering and heatmap (PSP vs C): Left: Clustering with respect to samples (above), clustering 
with respect to proteins (below). Right: The rows represent proteins, and the columns represent PSP and Control samples. 
All upregulated proteins are red in color and downregulated proteins are blue in color. The ones in white are those that show 






Figure 7.1: Clustering of samples in the experimental conditions for the pairwise comparison in AD vs PSP and 









Figure 7.2: Hierarchical Clustering and heatmap (AD vs PSP): left: Clustering with respect to samples 
 (above), clustering with respect to proteins (below). Right: The rows represent proteins, and the columns represent AD and 
PSP samples. All upregulated proteins are red in color and downregulated proteins are blue in color. The ones in white are 












2.2.6.4: Venn diagrams:  
To see the extent of overlapping proteins and unique proteins across the three pairwise comparisons, 
namely AD vs. C, PSP vs. C and PSP vs. AD, a Venn diagram (Figure 8.1) was plotted using the Venn 
diagram package in R with adjusted p-value cut-off adj-p < 0.05. Two other Venn diagrams were 
plotted to visualize just the upregulated proteins (Figure 8.2) and (Figure 8.3) in all three pairwise 
comparisons.  
 
Figure 8.1: Venn diagram showing the overlap of all proteins in the three comparisons. (AD vs C, PSP vs C, AD vs 
PSP).  With respect to AD: The blue represents 43 proteins unique to AD. There are 37 proteins overlapping between AD 
vs Control and PSP vs Control. 14 proteins are common between the three pairwise comparisons (AD vs C, PSP vs C, AD 
vs PSP). With respect to PSP: The green represents 27 proteins unique to PSP. With respect to AD and PSP: The yellow 










Figure 8.2: Venn diagram showing the overlap of all up regulated proteins in the three comparisons. (AD vs C, PSP 
vs C, AD vs PSP). With respect to AD: The blue represents 21 unique proteins upregulated in AD. 3 proteins are common 
between the three pairwise comparisons (AD vs C, PSP vs C, AD vs PSP). With respect to PSP: The green represents 158 















Figure 8.3: Venn diagram showing the overlap of all down regulated proteins in the three comparisons. (AD vs C, 
PSP vs C, AD vs PSP). With respect to AD: The blue represents 22 unique proteins that are down regulated in AD. 2 
proteins are common between the three pairwise comparisons (AD vs C, PSP vs C, AD vs PSP). With respect to PSP: The 
green represents 71 proteins unique to PSP. With respect to AD and PSP: The yellow represents 1075 proteins unique to 

















2.2.6.5: Volcano plots:  
Volcano plots were also plotted to visualize up and down regulated proteins across pairwise comparison 
of the three conditions AD, Control and PSP using EnhanceVolcanoPlot, an R package. The significant 
proteins (with P < 0.05 and log2fc >=0.3 and >=-0.3) are highlighted in red. Those highlighted in black 
are the proteins with non-significant differences in expression levels, and those highlighted in green 
are proteins with log2fc >= 0.3 and >= -0.3 in all the pairwise comparisons AD vs. C, PSP vs. C and 




Figure 9.1: Volcano plot showing all dysregulated proteins in AD vs C. The significant proteins (with P < 0.05 and 
log2fc >=0.3 and >=-0.3) are highlighted in red. Black = proteins with non-significant differences in expression levels, 











Figure 9.2: Volcano plot showing all dysregulated proteins in PSP vs C. The significant proteins (with P < 0.05 and 
log2fc >=0.3 and >=-0.3) are highlighted in red. Black = proteins with non-significant differences in expression levels, 










Figure 9.3: Volcano plot showing all dysregulated proteins in PSP and AD. The significant proteins (with P < 0.05 and 
log2fc >=0.3 and >=-0.3) are highlighted in red. Black = proteins with non-significant differences in expression levels, 
green = proteins with log2fc >=0.3 and >=-0.3. 
 
2.2.6.6: Box Plots:  
We wanted to check the distribution of protein expression for each condition. So, we plotted boxplots 
(AD vs C, PSP vs C, AD vs PSP).  The x-axis represents samples for all pairwise comparisons (AD 
and Control, PSP and Control, AD and PSP), and y-axis represents their protein expression. We 
observed that for proteins C9JTJ8, HCN4 and CO1A1, the protein expression levels are high compared 




















Figure 10.3: Boxplots for AD vs PSP. The protein expression levels are high for C9JNG9, F5HD6, H0YD17, PRELP.  
 
2.2.6.7: Enrichment analysis of pathways and process: 
After performing a DEP analysis and obtaining significant DEPs, they were used for functional 
enrichment analysis of the pairwise comparison AD vs. C. The functional enrichment analysis consisted 
of KEGG pathways, Gene Ontology process. Protein-protein interaction networks were constructed. 
 
2.2.6.7.2: Gene Ontology and KEGG pathways: 
To look at the common pathways and cellular processes shared by the proteins of interest, KEGG 
pathway analysis and Gene Ontology were performed.  
KEGG pathways: KEGG pathways tell us about various biochemical processes like metabolism, 






Figure 11.1: KEGG pathways in AD vs. C 
 
 
Gene Ontology: Gene Ontology provides information about gene functions and relationships between 
the functions along with three aspects, namely Biological Processes (larger processes of the genes), 
Molecular Function (molecular activities of the gene), and Cellular Component (which part of the cell, 












a. GO: BP 
 
             Figure 11.2: Gene Ontology of Molecular Functions in AD vs C 
 
 
b. GO: MF 
 







c. GO: CC 
 
Figure 11.4: Gene Ontology of Cellular Component in AD vs. C 
 
2.2.6.7.3: Protein-Protein Interactions for hub proteins: 
It is essential to study proteins and their functional interactions to understand the complete biological 
phenomenon within a cell. So, we performed a Protein-protein interaction (PPI) enrichment analysis in 
STRING DB among the list of proteins that were significantly dysregulated to identify the group of 
proteins that have a similar function (functional association refers to a link between two proteins that 
both contribute jointly to a specific biological process) and belong to the same pathway rather than 
looking at the physical interactions. The interaction scores in STRING do not represent the strength or 
specificity of a given interaction. Instead, they are meant to express approximate confidence on a scale 
of zero to one. The scores in STRING are benchmarked using the subset of associations for which both 
protein partners are already functionally annotated (STRING v11- Szklarczyk et al., 2019). So, the hub 















2.3: Differential expression analysis of RNA seq: 
 
We performed the differential expression analysis of RNAseq transcript counts (gene profiling) data 
following the tutorial https://bioinformatics-core-shared-training.github.io/RNAseq-R/. The data used 
for the analysis was downloaded from synapse.org (synapseID: syn20818651) named 
“Mayo_RNAseq_TCX_transcriptCounts.tsv”. We chose to process transcript counts for further 
analysis. 
2.3.1: Quality Control (QC): 
Transcripts with very low counts across all libraries provide little evidence for differential expression 
and so have to be filtered out. To filter out lowly expressed genes, we filtered on a minimum counts 
per million (CPM) threshold present in at least 31 samples. 31 represents the smallest sample size (in 
the Control group) for each group in our experiment. We choose to retain genes if they are expressed 
at a CPM above 1 in at least 31 samples. We used the cpm function from the edgeR library to generate 
the CPM values. By converting to CPMs we normalized for the different sequencing depths for each 
sample. Next, we created a DGEList object. (This is an object used by edgeR to store count data.) To 







Figure 12: Bar plot of library sizes: Plots of the library sizes as a bar plot to see whether there are any major 
discrepancies between the samples more easily. 
 
 
From the plot, we can see that Count data is not normally distributed, so if we want to examine the 
distributions of the raw counts, we need to log the counts. Next, we used box plots to check the 
distribution of the read counts on the log2 scale. We can use the cpm function to get log2 counts per 
million, which are corrected for the different library sizes. The cpm function also adds a small offset to 






Figure 13: Box plots to check the distribution of the read counts on the log2 scale. 
 
From the boxplots we see that overall, the density distributions of raw log-intensities are not very 
identical but still not very different. We used the plotMDS function to create the multidimensional 





Figure 14: MDS Plot: We used the plotMDS function to create the multidimensional (MDS) plot. We color-coded 







After checking the quality of our data, we normalized the data using  trimmed mean of M-values 
normalization method (TMM) embedded in edgeR, to eliminate composition biases between libraries. 
The calcNormFactors function in edgeR calculates the normalization factors between libraries. The 




the plotMD function for these samples, we saw the composition bias problem. We used the logcounts, 








Since our DGEList object contains the normalization factors, plots using dgeObj (normalized 








Figure 15b: The normalized mean-difference plots show average expression (mean: x-axis) against log-fold-
changes (difference: y-axis). 
 
After normalization, we performed the differential expression analysis between AD and Control, PSP 
and Control, AD and PSP. We kept the same p-value and fold-change cut offs as  in proteomics data 
analysis. (adj.P-value < 0.05, logFC = 0.03). The list of genes are attached as an appendix. As a part of 
inferential statistical analysis, to visualize how the sample and gene clusters are grouping themselves, 
we performed clustering and visualized our samples with heatmaps. We plotted Venn diagrams to check 
the overlap of common genes and to see how many genes were unique to a particular class of 




also plotted box plots to check the distribution of genes abundances in each condition in comparison 
with control (Attached in Appendix).  
2.4: Correlation analysis: 
 
Correlation analysis is a statistical method of looking at the strength of pairing between two variables. 
The central dogma of molecular biology has laid in simple and direct terms that DNA makes RNA 
makes proteins but there is substantial precariousness to it. Correlations are found to exist between the 
levels of RNA and their corresponding proteins. However, we wanted to see if there existed any 
correlations between genes from a data set (RNAseq) and proteins from another dataset (proteomics). 
So, alongside looking at the correlations within each -omics layer, we wanted to check if there existed 
any correlations between the two omics layers using Spearman’s correlation coefficients method. We 
used Spearman's correlation coefficients because they are rank-based and are robust for logarithmic 
data in contrast to Pearson's correlation coefficients which could be strongly biased by extreme values 
[30]. Firstly, we wanted to see if there are any interactions within proteins from the proteomics data 
set. Secondly, we looked at the interactions within genes in the RNAseq data set. Finally, we looked at 
correlations between proteins that were obtained from proteomics and genes obtained from RNAseq. 
We obtained our input data for correlation analysis from the individual differential expression analysis 
of proteins and genes. For example, to get the set of proteins involved in AD, we selected from the 
normalized data and from the normalized and log2-transformed protein data only those samples that 
are also in the RNA data. In the proteomics dataset, 1:31 were Control columns, 32:115 were AD 
columns and 116:200 were PSP columns (where columns are samples). We removed three samples that 






Thus, we have equal sample size. 
 
Proteins: Number of samples: AD = 82, PSP = 84, Control = 31 
Genes: Number of samples: AD = 82, PSP = 84, Control = 31 
 
2.4.1: Correlation analysis of proteins involved in AD with proteins of all samples: 
We selected AD proteins (N = 114) obtained from AD vs. Control and looked for them in the complete 














2.4.2: Correlation analysis of genes involved in AD with genes in all samples: 
We selected AD genes (N = 61) obtained from AD vs. Control and looked for them in the complete 
data consisting of AD, Control, and PSP samples.  
 





2.4.3: Correlation analysis of proteins and genes involved in AD with proteins and 
genes in all samples: 
We performed correlation between 114 AD proteins and 61 AD genes obtained from AD vs. Control 








Figure 16.2: Correlation plots of proteins and genes involved in AD with all proteins genes of all samples. 
 
Chapter 3: Results and Discussion 
 
 
3.1: Enrichment analysis: 
 
As mentioned in the methods section, an enrichment analysis consisting of significant DEPs was 
performed. To see which proteins are functionally related, we performed a functional enrichment 
analysis for the pairwise comparisons AD vs Control consisting of ARCHS4 Co-expression, KEGG 
pathways, GO annotations and PPI hub proteins. All of these proteins are seen dysregulated in AD 
according to our analysis and to a large extent are supported by rich literature evidence. However, cross 
validation with lab experiments is essential. 
 
 
3.1.1: KEGG pathways: 
 
We found 42 unique genes involved in 83 pathways. The top genes are involved in ECM-receptor 
interaction, Calcium signaling pathway, Glucagon signaling pathway, and Alzheimer’s Disease 
pathway.  
 
Table 5.1: KEGG pathways of proteins in AD 
 
Term Genes 
ECM-receptor interaction SPP1;ITGA6;CD44 
Calcium signaling pathway P2RX7;ATP2B4;PHKA1;PLCD3 
Glucagon signaling pathway PGAM2;PHKA1;PYGL 










3.1.2: Gene Ontology: 
 
BP: We found 834 processes shared by 153 unique proteins. The top genes in GO terms involved in 
biological process like triglyceride catabolic process (GO:0019433) were FABP3; FABP7; APOE, the 
proteins involved in cellular response to growth factor stimulus (GO:0071363) were ANXA1; STMN2; 
HSPB1; MAPT; CD44, and extracellular matrix organization (GO:0030198) were FGA; HTRA1; 
SPP1; ADAM10; ITGA6; CD44respectively. 
 
 
Table 5.2: Gene Ontology Biological Process pathways of proteins in AD 
 
Term Genes 
triglyceride catabolic process (GO:0019433) FABP3; FABP7; APOE 
cellular response to growth factor stimulus 
(GO:0071363) 
ANXA1; STMN2; HSPB1; MAPT; CD44 





MF: We found 134 molecular functions shared by 51 unique proteins. The top genes in GO terms 
involved in molecular function like protein homodimerization activity (GO:0042803) were 
P2RX7;GSTM3;HSPB6;QPRT;HSPB1;ADAM10;PYGL;MAPT;APOE, the proteins involved in 
intermediate filament binding (GO:0019215) were SYNM;VIM, cadherin binding (GO:0045296) were 
ANXA1;BAG3;ITGA6;CAPG;PLEC, and calmodulin-dependent protein kinase activity 









protein homodimerization activity 
(GO:0042803) 
P2RX7;GSTM3;HSPB6;QPRT;HSPB1;ADAM10;PYGL;MAPT;APOE 
intermediate filament binding (GO:0019215) SYNM;VIM 
cadherin binding (GO:0045296) ANXA1;BAG3;ITGA6;CAPG;PLEC 






CC:  We found that 93 cellular components were shared by 40 unique proteins.  Proteins involved in 
Focal adhesion (GO:0005925) were ANXA1; CSRP1; FHL1; HSPB1; ADAM10; ITGA6; VIM; 
CD44;CD99;SNTB1;PLEC, proteins in the intermediate filament cytoskeleton (GO:0045111) were 
SYNM;VIM;PLEC, proteins involved in polymeric cytoskeletal fiber (GO:0099513) were 































3.1.3: Protein-Protein Interactions and hub proteins: 
 
Below is the snapshot of protein-protein interactions generated by STRING DB which consider the 
functional context of proteins based on the pathways and processes taken by the protein sets. For 
example, the protein ABCC8 in the figure below (figure 11.5 from methods section), is functionally 
associated with other proteins that have the function - ATP-binding cassette sub-family C member 8; 
Subunit of the beta-cell ATP-sensitive potassium channel (KATP). Regulator of ATP-sensitive K(+) 
channels and insulin release; ATP binding cassette subfamily C. The protein ABL1 is functionally 
associated with proteins that have function as Tyrosine-protein kinase ABL1; Non-receptor tyrosine-
protein kinase that plays a role in many key processes linked to cell growth and survival such as 
cytoskeleton remodeling in response to extracellular stimuli, cell motility and adhesion, receptor 
endocytosis, autophagy, DNA damage response and apoptosis. Coordinates actin remodeling through 
tyrosine phosphorylation of proteins controlling cytoskeleton dynamics like WASF3 (involved in 
branch formation); ANXA1 (involved in membrane anchoring); DBN1, DBNL, CTTN, RAPH1 and 
ENAH (involved in signaling); or MAPT and PXN (microtubule-binding [...] and ACTA1 is 
functionally associated with proteins that have function as Actin, alpha skeletal muscle; Actins are 
highly conserved proteins that are involved in various types of cell motility and are ubiquitously 
expressed in all eukaryotic cells. We found 156 proteins that act as hub proteins and are associated with 
other proteins functionally as predicted by STRING DB. (The figure is same as mentioned in methods 




















3.2: Correlation analysis: 
When we performed a correlation analysis of proteins involved in AD with proteins in all samples, we 
found 12,996 protein-protein pairs. We then filtered the correlations at p-value = 0.00001 and got 2520 
significant correlations. The mean correlation coefficient was 0.54. We further increased the stringency 
of the p-value and obtained 192 very significant correlations (p-value <= 0.00000000000005). Mean 
correlation coefficient = 0.52. (A snapshot of a few is attached below as a table (Table 5.1). The whole 
list is attached as a supplementary table). We find that most proteins form very significant protein-
protein pairs. 
 
Table 6.1: Correlations between proteins involved in AD 
 


















































































B0YJC5 Vimentin VIM F8VRJ1 Rabphilin-3A RPH3A -0.542964494 
2.22E-
16 

























Fatty acid-binding protein, 
brain 
































































































































Similarly, we performed a correlation analysis of genes involved in AD with genes in all samples, we 
found 3,721 gene-gene pairs. We then filtered the correlations at p-value = 0.00001 and got 2266 




stringency of the p-value and obtained 208 very significant correlations (p value <= 0.0000000000005). 


























Table 6.2: Correlations between genes involved in AD 
Gene
ID1 Protein Name  Gene Name 
GeneI














































































Regulator of G-protein 
signaling 1 











































Solute carrier family 13 
member 4 SLC13A4 SUT1 
KRT3
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1 Desmoplakin DSP 
MPZL
2 
Myelin protein zero-like 
protein 2 










type 2 IL1R2 IL1RB EMP1 
Epithelial membrane 












immunoglobulin gamma Fc 














cysteine-rich type 1 protein 








































Solute carrier family 13 













We performed a correlation analysis of proteins and genes involved in AD with proteins and genes in 
all samples, we found 6954 protein-gene pairs that were correlated. We then filtered the correlations 
(p-value = 0.0001) and got 395 significant correlations. The correlation coefficient was a high value of 


























We then wanted to look at the patterns of correlations between proteins and genes. So, we first sorted 
the proteins alphabetically with their corresponding correlation coefficients and p-values. It was 
fascinating to observe that there were at least 30 protein-gene pairs in which a single protein was found 




Microtubule-associated protein tau and can be found in biological databases as MAPT, MAPT1, 
MTBT1, and TAU. As already mentioned in the introduction section, hyperphosphorylation of tau 
protein is a hallmark of neurodegeneration in AD. Here in the table 5.4 below, we can see that tau 
protein shows significant correlations with at least 14 genes namely, H7BZ97 (Integrins – delay the 
loss of neurons in AD), GTD2A (several transcription factors are involved in AD regulatory networks), 
NDUV3 (contributes to alterations of oxidative metabolism in AD), IP3KB (increased in human AD), 
E5RG36CON_P17697 (no information, could be novel protein/gene which requires evidence at 
molecular level), A6NMN0 (gene name: PHKA1 differentially expressed in AD mice), GSE968 (gene 
name: CHGA is downregulated in AD), A0A096LP69 (CD99 antigen plays a key role in AD 
inflammation), E9PMM2 (UBTF: upstream nuclear transcription factor  is a nuclear chaperone whose 
expression is decreased in AD), AHNK (literature suggests a strong connect between APOE gene and 
AHNK), NPTX2 (reduced expression in AD), H7C0X8 (macrophage capping protein), ACTN2 (highly 



















Similar to above correlations where a single protein is found to be associated with multiple genes, it 
was also fascinating to observe that a single gene is forming pairs with multiple proteins, which was 
obtained by sorting genes alphabetically along with their corresponding correlation coefficients and p-
values. We found more than 32 such correlations, an instance can be seen in the table below, most of 





















Below is the interpretation of pairing between proteins and genes: 
Table 6.6: Biological interpretations of the correlations between proteins and genes with r >=0.45. Correlation 
analysis depicting association of proteins with genes involved in AD to see the direction of association patterns 
 
Protein Gene Correlation Coeff. P-val 
C9J3N8 
E5RG36CON__P1769
7 0.5348593 4.44E-16 
E5RG36CON__P17697 IP3KB 0.53832742 4.44E-16 
C9JFK9 IP3KB 0.50479345 3.91E-14 
G5E968 NPTX2 0.49616811 1.22E-13 
C9JFK9 
E5RG36CON__P1769
7 0.49506646 1.41E-13 
G5E968 PGAM2 0.49435282 1.55E-13 
C9J3N8 G5E968 0.49295656 1.86E-13 
C9J3N8 A6NMN0 0.48992556 2.74E-13 
ARAID H7BZ97 0.48963984 2.84E-13 
TAU.1 H7BZ97 0.48589622 4.56E-13 
C9JFK9 G5E968 0.48109284 8.32E-13 
E5RG36CON__P17697 A6NMN0 0.47614383 1.53E-12 
C9JFK9 A6NMN0 0.47108802 2.82E-12 
CO4A H7BZ97 0.4586358 1.22E-11 
E5RG36CON__P17697 H7BZ97 0.45235458 2.50E-11 
D6R9C5 NPTX2 0.45120781 2.85E-11 
Protein Gene Corelation  Coeff.  P-value 
H3BV46 G5E968 -0.428894 3.21E-10 
H3BV46 A6NMN0 -0.42876371 3.26E-10 
H3BV46 H7BZ97 -0.41958821 8.39E-10 
Q05BJ3 H7BZ97 -0.4119914 1.80E-09 
 
 
Correlations between C9J3N8, IP3KB, C9JFK9, A6NMN0, H7BZ97, and E5RG36CON__P17697: 
C9J3N8 is a heat shock protein (HSP Beta 1). Heat shock proteins (HSPs) like Hsp60, and Hsp70 that 
play the role of molecular chaperones in the cell have a range of functions to maintain cellular 
homeostasis when they face stress. They are found associated with stopping APP/Aβ protein folding, 




C9J3N8 is highly correlated (r = 0.53) with a gene of unknown information 
(E5RG36CON__P17697) in the biological database (Ensembl). While we could find all the proteins 
and genes are annotated in the biological databases like UniProt and Ensembl, there was a protein by 
the ID ‘E5RG36CON__P17697’ which was found significantly correlated at both gene and protein 
levels, but we found no information about it. So, this could be our novel gene/protein. However, it can 
be further confirmed with immunoprecipitation/immunofluorescence protocols. The study of these high 
correlations between HSPs and AD is a significant area of research. mRNA levels of ITPKB gene 
(protein name Inositol-trisphosphate 3-kinase B and gene ID IP3KB) are significantly increased in AD 
[44]. This gene is seen forming protein - gene pairs with protein E5RG36CON__P17697 and protein 
C9JFK9 having very high correlations r >= 0.50. C9JFK9 (BAG family molecular chaperone regulator 
3) also belongs to the family of molecular chaperones. BAG3 facilitates clearing off of tau protein, 
which, due to its hyperphosphorylation, causes neurodegeneration and aggressiveness of AD 
[45]. From the above information, and based on the correlations, we observe that 
E5RG36CON__P17697 has a positive relationship with C9J3N8, IP3KB, C9JFK9. This gives us an 
insight that E5RG36CON__P17697 might also be a protein/gene which might be associated with a 
function that opposes the progress of AD. A6NMN0 is a subunit of PHKG2 (Phosphorylase b kinase 
gamma catalytic chain) and mediates neuronal regulation of glycogen breakdown by phosphorylating 
and thereby activating glycogen phosphorylase. The catalysis of the reaction: ATP + tau-protein = ADP 
+ O-phospho-tau-protein. There is a tight coupling between glycogen breakdown and neuronal 
development. Studies show that glucose levels are reduced in AD [46]. While we discussed above 
that E5RG36CON__P17697 is associated with molecular chaperones, which aid in stopping the 




with A6NMN0 which mediates glucose metabolism.  Aβ interacts with integrin subunits 
(H7BZ97/ITGA6) in the early onset of AD [47,48].  
 
Correlations between C9JFK9 and IP3KB and association with E5RG36CON__P17697:  
C9JFK9 is a molecular chaperone that interacts with ITPKB gene whose mRNA levels are increased 
in AD. E5RG36CON__P17697 positively correlated with ITPKB and C9JFK9. 
We can see from the associations that these proteins and genes could probably be very well associated 
with AD and could be significant research areas for their therapeutics. 
 
Correlations of G5E968 with NPTX2, PGAM2, C9J3N8, C9JFK9, and H3BV46: 
In AD, about 30% of beta-amyloid plaques co-labeled with proteins chromogranin A (Gene 
ID G5E968). A study shows that Chromogranin A might be a mediator amongst neuronal, glial, and 
inflammatory mechanisms found in AD [49]. 
Neuronal pentraxin-2 (gene ID NPTX2) levels are reduced in AD leading to cognitive dysfunction [50]. 
PGAM2 is a hub protein that is enriched in AD-related pathways [51]. A study by Chen, Lu et al., 2019 
shows that BAI1-associated protein 3 (Gene ID H3BV46) is downregulated in AD. We observe from 
our analysis that G5E968 is positively correlated with NPTX2, PGAM2, C9J3N8, C9JFK9 (r = 
0.49) and negatively correlated with H3BV46 (r = -0.42).  
 
Correlation of H7BZ97 with ARAID, TAU.1, CO4A, E5RG36CON__P17697 and H3BV46, Q05BJ3:   
H7BZ97 is also an integrin (protein name – Integrin alpha 6 - ITGA6). As discussed above, Aβ protein 
that forms amyloid plaques in AD, interacts with integrin subunits. We couldn’t find enough 




association with AD. CO4A is associated with neuroinflammation in AD [52]. TAU.1 (MAPT1) is 
highly hyperphosphorylated in AD [53]. As already discussed above, BAI1-associated protein 3 
(H3BV46) is downregulated in AD [54]. Peptides derived from VGF (Q05BJ3 (Protein name- 
Neurosecretory protein VGF) are reduced in cerebrospinal fluid of AD patients which helps against 
advancement of AD [55,56]. From our analysis, we see that H7BZ97 is positively 
correlated with ARAID (r = 0.48), TAU.1(r = 0.48), CO4A (r = 0.45), and E5RG36CON__P17697 (r 
= 0.45) but is negatively correlated with H3BV46 (r = -0.41) and Q05BJ3 (r = -0.41). However, all of 



















Chapter 4: Conclusion  
 
Genes are the basic unit of hereditary material in any living organism. Proteins are complex molecules 
that play critical roles in an organism. Most genes contain the information required to make proteins 
but the process of formation of proteins from genes is a complex journey within the cell which involves 
complex gene regulation. So, it is difficult to understand the relationship between them. There are also 
factors like transcription factors, RNA binding proteins (RBPs) and regulatory factors should be studied 
if we were to study the interactions between genes and proteins. A study by Koussounadis et al., 2015 
shows that significantly higher correlations occur between mRNA and protein for genes with 
differentially expressed mRNA.   Zaborowski and Walther, 2020 in their paper mentioned that while 
transcription factors (TFs) are known to regulate the expression of their target genes (TGs), only a weak 
correlation of expression between TFs and their TGs has generally been observed. So, since ours is a 
data driven approach and validation via immunoprecipitation is further needed to understand the 
interactions or interplay between genes and proteins, and while it's known that correlation doesn’t imply 
causation, we just wanted to see what correlations existed between proteins and genes without a focus 
on the actual interactions.  From our analysis, we have seen that TAU protein, APOE genes, and 
amyloid-beta (Aβ) proteins are significantly dysregulated in AD and play a significant role in the 
progression of the disease in accordance with literature and past research. We also observed that they 
are seen being in an association with a number of other proteins and genes that further advance the 
disease and are also seen pairing with proteins and genes that act as molecular chaperones which is a 
very interesting area of research.  It was also fascinating to see the gene/protein E5RG36CON__P17697 
is associated in different ways with a set of proteins and genes. We can thus conclude that there could 




and processes as well as those that act in opposition to neurodegeneration could probably either be 
biomarkers that can detect the disease at an early stage and/or be the targets for therapeutics that are 
disease-modifying. To be able to understand what actually the mechanism at the molecular level is, 























Chapter 5: Challenges in the current work 
 
Whereas analysis of individual datasets is not very robust for the derivation of biological insights, large 
datasets obtained from high throughput technologies have revolutionized biology research. However, 
it is challenging to work with these huge datasets. The three most important areas of the challenge with 
-omics datasets are integration, interpretation, and extracting biological insights from the data (Misra 
et al., 2018). Before the integration of the data, each data set has to be filtered, cleaned, imputed, 
normalized, and scaled in such a way that the biological insights are reached. Correcting the proteomics 
dataset for batch effects was the most time taking and challenging step. Secondly, there is a large 
variation of sample sizes and abundance quantities which had to be taken care of. Thirdly, when 
integrating the DEPs and DEGs, the most challenging part was to look for them in the raw datasets 
based on the experimental conditions. We wanted to look for the proteins and genes differentially 
expressed in the pairwise comparisons (AD vs. C) in the complete data consisting of AD, PSP, and 
Control samples. After having done this step, given thousands of significant correlated proteins and 
genes, it was a challenge to search the literature to understand the biological insights that aligned with 











Chapter 6: Future work 
 
Studies show that a lot of research is being done in various ways to study AD. With the evolution of 
next-generation sequencing technologies and mass spectrometry technologies, it is becoming possible 
to use artificial intelligence in healthcare. It is thus getting more interesting to study disease causes and 
correlations. In the current study, we procured proteomics and RNA seq data to perform analysis. 
Initially, as we began, we performed a pairwise differential expression of AD vs. C, PSP vs. C and AD 
vs. PSP for both the datasets. In the correlation analysis, we focused only on AD proteins and genes. 
One great focus scope is definitely to look at the correlations with respect to PSP which is not done in 
this project. Future work could probably also include the integration and correlation analysis of more 
datasets that would facilitate in studying the aspects of epigenetics (DNA methylation, histone 
modifications, chromatin accessibility transcription binding sites), SNPs, CNVs, SAVs, loss of 
heterozygosity, finding rare variants, etc. to get a complete picture of the intricate molecular processes 
involved in the disease. Another good way could be making use of univariate, multivariate, and 
predictive analytics (machine learning and deep learning models) that can help predict the disease in 
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